Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 1199

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 11
Chunk 1199
---
 rare cancers. Through this collaboration, the Company will
apply its proprietary Bullfrog Data Networks™ solution, powered by the bfLEAP® platform, to analyze clinical data from Eleison’s
ongoing Phase III trial and previous clinical studies of glufosfamide, an investigational treatment for pancreatic cancer. The platform
will evaluate the current trajectory of the trial with respect to safety signals, extract predictive biomarkers for efficacy and safety
performance from prior studies to support future trial design, and provide data-driven insights to optimize Eleison’s planned clinical
trials for inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). These insights are expected to streamline trial efficiency
and improve decision-making for Eleison’s broader oncology pipeline.

In
March 2025, the Company anticipates making a severance payment to a former employee for approximately $45,000.

 F-18